4MOVING-BIOTECH
4Moving Biotech, a spin-off of 4P-Pharma committed to developing first-in-class treatments to modify the natural course of knee osteoarthritis, announces the successful achievement of the Phase 1 Lasare trial in knee osteoarthritis (OA) patients using 4P004.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240609275171/en/
(Graphic: Business Wire)
Lasare Phase I trial is a multi-center, randomized, double-blinded, placebo-controlled involving 34 patients across three sites in Belgium.
The study evaluated the safety, tolerability, and pharmacokinetics of ascending doses of a single intra-articular injection of liraglutide (4P004).
The trial reached its primary objective, confirming that intraarticular liraglutide (4P004) was safe and well tolerated. A pharmacological active dose has been identified, with similar expected adverse events (EAEs) in the 4P004 groups as the placebo group. Pharmacokinetics, both observed and simulated Cmax values, also indicated lower systemic exposure than reported for subcutaneous liraglutide injection from the approved product, Victoza®, affirming the company’s plan to pursue a 505(b)(2) regulatory pathway in the US for 4P004.
Pr. Francis Berenbaum, Co-founder and Chief Medical Officer of 4Moving Biotech, declared: "The Success of the Phase 1 study of 4P004 underscores the quality of our advancements in the quest for therapeutic solutions for patients suffering from knee osteoarthritis. Furthermore, with the established safety and tolerability profiles, we are progressing confidently to the next stage of clinical development with 4P004."
As for ultimate goal, 4Moving Biotech’s strategy intends to secure accelerated approvals in the US and EU for early market entry at the end of the planned Phase 2b efficacy and safety trial. Toward this goal, the company recently received constructive pre-IND guidance from the FDA, translating 4Moving Biotech’s planned potential accelerated approval driven strategy into a highly differentiated clinical program catalyzed by a unique combination of reasonably likely surrogate endpoints, supported by sophisticated in silico AI-based prognostic modelling.
Revital Rattenbach, Chairwoman of 4Moving Biotech, stated: "Beyond the positive results from our phase I clinical study on knee osteoarthritis, the FDA's positive echoing has built a tremendous momentum for our accelerated strategy to the market, with hopes to bring to OA patients the first therapy being able to modify the natural course of the disease."
About 4Moving Biotech
Incorporated in mid 2020 as a spin-off of 4P-Pharma, 4Moving Biotech is a clinical stage biotechnology company dedicated to the development of the Disease-Modifying Osteoarthritis Drug (DMOAD). Its mission is to provide a sustainable therapeutic solution to the significant unmet medical need of osteoarthritis. The company is headquartered at the Pasteur Institute in Lille, France.
Website: https://www.4movingbiotech.com/
LinkedIn: https://fr.linkedin.com/company/4moving-biotech
About Lasare
This project has received funding from the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and innovation program. The funding agencies supporting this work are (in alphabetical order of participating countries): France: BPI France ; Germany: Project Management Agency (DLR), which acts on behalf of the Federal Ministry of Education and Research (BMBF); The Netherlands: Netherlands Enterprise Agency (RVO); Switzerland: Innosuisse (the Swiss Innovation Agency).
The only version of the 4Moving Biotech press release that is legally binding is the one in its original language. Translations must always be compared to the source text, which will establish precedence. The press release text resulting from a translation should not be considered official in any way.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240609275171/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Amazfit Expands Active 2 Lineup with the New Active 2 Square — All the Same Features, Now in a Sleek Square Design17.6.2025 06:01:00 CEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), a health technology company, today announced the launch of the square version of the Amazfit Active 2, a new addition to its fitness smartwatch line that offers the same powerful features and premium experience as the recently launched round Active 2 — now in a modern, square form factor. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250616213563/en/ Amazfit Active 2 Square Same Features. New Shape. Debuting at CES 2025 and featured at Pepcom and ShowStoppers, the Active 2 Square is designed for consumers who prefer a bold, geometric aesthetic without compromising performance, durability, or advanced health and fitness tracking. Featuring a square, 1.75 inch sapphire glass high-definition AMOLED display elegantly encased in a polished stainless-steel frame, the Amazfit Active 2 delivers an optimal visual experience with a peak brightness of 2,
Agileo Automation Announces Future Expansion Of A2ECF-SEMI Automation Framework With SEMI EDA Standards17.6.2025 06:00:00 CEST | Press release
Integration of EDA empowers OEMs to deliver structured, high-bandwidth data to semiconductor fabs and drive efficiencies for competitive advantage CEA LID World Summit –Agileo Automation, a leading provider of control and connectivity solutions for global semiconductor manufacturing equipment, today announced the future expansion of its A2ECF-SEMI automation framework to include SEMI’s EDA (Equipment Data Acquisition) standards suite. This integration that already includes Agil’GEM and Agil’GEM300 will empower OEMs to deliver structured, high-bandwidth data to manufacturing facilities and drive process improvements with artificial intelligence (AI) by leveraging large amounts of reliable, actionable data. EDA standards, built on the legacy of SECS/GEM and GEM300, are transforming equipment communication and enabling high-speed, data-driven manufacturing.As semiconductor fabs become more connected and automated, the ability of OEM equipment to integrate seamlessly and deliver high-quali
Ant International Empowers Partners to Serve Over 15 Million Customers Globally with Intelligent Credit Tech Solutions17.6.2025 03:00:00 CEST | Press release
Ant Credit Engine helps financial service providers make faster and smarter credit decisions at scale Through its credit tech solutions, Ant International has enabled financial institutions and fintech companies to extend credit access to over 15 million customers, including micro, small and medium-sized enterprises (MSMEs) in emerging markets, according to Quan Yu, General Manager of Credit Services, Ant International. Ant International is a global leader in digital payments, digitisation and financial technology. Millions of MSMEs and individuals remain underserved due to the lack of collaterals, stable income or credit history. To serve these segments and grow business, financial service providers need intelligent credit tech solutions powered by alternative data and embedded in their existing systems. The Ant Credit Engine, one of the core innovative offerings developed by Ant International, is an intelligent and automated credit engine. It helps financial institutions, fintechs, e
Lattice to Showcase FPGA Innovations at FPGA Conference Europe 202516.6.2025 22:00:00 CEST | Press release
‒ Pravin Desale, Head of R&D, to Deliver Opening Speech on Growing Need for Low Power FPGAs ‒‒ Multiple Speaker Sessions Focused on Edge AI, Sensor Fusion, Industrial IoT, Ethernet Solutions, Design Tools, and More ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced its exhibition plan for the upcoming FPGA Conference Europe. As part of the event, Lattice Senior Vice President of Research and Development Pravin Desale will deliver an opening speech where he will explore the market dynamics and trends that are positioning low power FPGAs at the forefront of technological advancements. In addition, Lattice will participate in various speaker sessions to showcase how low power FPGAs are driving innovation across multiple sectors. The company will also demonstrate its latest FPGA technology advancements in edge AI, advanced connectivity, robust security, and more. Who: Lattice Semiconductor What / When (GMT+2): July 1 – 3: Lattice Demo Showcase (Exhib
Verimatrix Receives 2025 Intellyx Digital Innovator Award16.6.2025 17:45:00 CEST | Press release
Regulatory News: Verimatrix, (Euronext Paris: VMX), the leader in powering the modern connected world with people-centered security, today announced it won the 2025 Intellyx Digital Innovator Award. Recognizing the innovation within Verimatrix Extended Threat Defense (XTD), the prestigious accolade underscores the solution’s unique arsenal of defensive techniques including code obfuscation, anti-tamper technology, and environmental checks that shield mobile apps, detect threats, and respond to them effectively. Verimatrix XTD continually arms some of the world’s top mobile app brands with the latest security technologies to consistently protect their app-centric business. It’s the go-to security solution for organizations looking to proactively protect vital mobile apps from today’s wide range of threats such as supply chain attacks, screen overlays, application repackaging, illicit modification or tampering, man-in-the-device attacks, and more. XTD’s advanced obfuscation techniques as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom